Last reviewed · How we verify

Ipilimumab and nivolumab — Competitive Intelligence Brief

Ipilimumab and nivolumab (Ipilimumab and nivolumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immune checkpoint inhibitor combination (CTLA-4 inhibitor + PD-1 inhibitor). Area: Oncology.

phase 3 Immune checkpoint inhibitor combination (CTLA-4 inhibitor + PD-1 inhibitor) CTLA-4 and PD-1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ipilimumab and nivolumab (Ipilimumab and nivolumab) — Leiden University Medical Center. Ipilimumab and nivolumab together block immune checkpoints (CTLA-4 and PD-1) to unleash T-cell-mediated anti-tumor immunity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ipilimumab and nivolumab TARGET Ipilimumab and nivolumab Leiden University Medical Center phase 3 Immune checkpoint inhibitor combination (CTLA-4 inhibitor + PD-1 inhibitor) CTLA-4 and PD-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immune checkpoint inhibitor combination (CTLA-4 inhibitor + PD-1 inhibitor) class)

  1. Leiden University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ipilimumab and nivolumab — Competitive Intelligence Brief. https://druglandscape.com/ci/ipilimumab-and-nivolumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: